Compared with normal tissues, the RUNX1 expression increased in 15 cancers (bladder, brain, breast, cervical, colorectal, esophageal, gastric, head and neck, kidney, leukemia, lung, lymphoma, myeloma, pancreatic, and sarcoma cancers) and decreased in 7 cancers (breast, leukemia, lung, lymphoma, melanoma, prostate, and sarcoma cancers) (Figure 1A, left panel). Here, RUNX1 is linked to melanoma.